Literature DB >> 21763751

New insights into the mechanisms of activin action and inhibition.

Kelly L Walton1, Yogeshwar Makanji, Craig A Harrison.   

Abstract

Like other members of the transforming growth factor-β (TGF-β) superfamily, activins are synthesised as precursor molecules comprising an N-terminal prodomain and C-terminal mature region. During synthesis, the prodomain interacts non-covalently with mature activin, maintaining the molecule in a conformation competent for dimerisation. Dimeric precursors are cleaved by proprotein convertases and activin is secreted from the cell non-covalently associated with its propeptide. Extracellularly, the propeptide interacts with heparan sulfate proteoglycans to regulate activin localization within tissues. The mature activin dimer exhibits the classic 'open-hand' structure of TGF-β ligands with 'finger-like' domains projecting outward from the cysteine knot core of the molecule. These finger domains form the binding epitopes for type I and II serine/threonine kinase receptors. Activins ability to access its signalling receptors is regulated by the extracellular binding proteins, follistatin, follistatin-like-3, and by inhibins, which, in the presence of betaglycan, sequester type II receptors.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21763751     DOI: 10.1016/j.mce.2011.06.030

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  32 in total

Review 1.  Mechanisms controlling germline cyst breakdown and primordial follicle formation.

Authors:  Chao Wang; Bo Zhou; Guoliang Xia
Journal:  Cell Mol Life Sci       Date:  2017-02-14       Impact factor: 9.261

Review 2.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

3.  Identification and characterization of a novel heparan sulfate-binding domain in Activin A longest variants and implications for function.

Authors:  Evan Yang; Christina Mundy; Eric F Rappaport; Maurizio Pacifici; Paul C Billings
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

Review 4.  Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins.

Authors:  Ian B Robertson; Daniel B Rifkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-06-01       Impact factor: 10.005

Review 5.  Activins and Inhibins: Roles in Development, Physiology, and Disease.

Authors:  Maria Namwanje; Chester W Brown
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

6.  Activin A induces apoptosis of mouse myeloma cells via the mitochondrial pathway.

Authors:  Yuanyi Zhang; Yan Qi; Yang Zhao; Hongyan Sun; Jingyan Ge; Zhonghui Liu
Journal:  Oncol Lett       Date:  2017-12-11       Impact factor: 2.967

7.  Smad3 induces atrogin-1, inhibits mTOR and protein synthesis, and promotes muscle atrophy in vivo.

Authors:  Craig A Goodman; Rachel M McNally; F Michael Hoffmann; Troy A Hornberger
Journal:  Mol Endocrinol       Date:  2013-09-03

8.  RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.

Authors:  Jacqueline M Langdon; Sangjucta Barkataki; Alan E Berger; Chris Cheadle; Qian-Li Xue; Victoria Sung; Cindy N Roy
Journal:  Am J Hematol       Date:  2014-10-25       Impact factor: 10.047

9.  Variable signaling activity by FOP ACVR1 mutations.

Authors:  Julia Haupt; Meiqi Xu; Eileen M Shore
Journal:  Bone       Date:  2017-10-31       Impact factor: 4.398

Review 10.  Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

Authors:  Laura Breda; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.